Posted by Michael Wonder on 09 Nov 2021
Moderna files to expand the conditional marketing authorisation for its COVID-19 vaccine in the European Union to include children ages 6-11 years
9 November 2021 - Submission based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11.
Moderna today announced that it has submitted for a variation to the conditional marketing authorisation with the EMA for the evaluation of a 50 µg two dose series of mRNA-12731 in children ages 6-11 years.
